New pill shows promise for rare blood cancers in early trial
NCT ID NCT07612280
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new daily pill called JBI-802 in people with certain blood cancers (myeloproliferative neoplasms and MDS/MPN) who have too many platelets. The trial has two phases: first, finding a safe dose in about 30 adults, then checking if it works. Participants take the drug for up to 2 years if it helps and side effects are manageable.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JBI-802 (a drug that targets two proteins, LSD1 and HDAC6, to help control abnormal blood cell growth)
What this could lead to
If this trial succeeds, it could point toward a new oral treatment option for people with certain blood cancers who have too many platelets.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply to everyone. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hollywood Private Hospital
RECRUITINGNedlands, 6009, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Macquarie University
RECRUITINGSydney, New South Wales, 2109, Australia
-
Monash Medical Centre
RECRUITINGMelbourne, Victoria, 3168, Australia
-
Royal Adelaide Hospital
RECRUITINGAdelaide, South Australia, 5000, Australia
-
St Vincent's Hospital (Melbourne)
RECRUITINGMelbourne, Victoria, 3065, Australia
-
St. Vincent's Hospital Sydney Limited
RECRUITINGSydney, New South Wales, 2010, Australia
-
The Perth Blood Institute Limited
RECRUITINGPerth, Western Australia, 6000, Australia